Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Krop, Ian E × Kim, Sung-Bae González-Martín, Antonio Lorusso, Patricia M Ferrero, Jean-Marc Smitt, Melanie Yu, Ron Leung, Abraham C F Wildiers, Hans on behalf of the TH3RESA study collaborators #
Lancet Pub. Group
The Lancet Oncology vol:15 issue:7 pages:689-99
Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options. We aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent DM1 linked to trastuzumab, with treatment of physician's choice in this population of patients.